Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, Whiting SH, Ulahannan SV. Yarchoan M, et al. Among authors: stagg r. Cancer Res Commun. 2024 Apr 18;4(4):1100-1110. doi: 10.1158/2767-9764.CRC-24-0082. Cancer Res Commun. 2024. PMID: 38551394 Free PMC article. Clinical Trial.
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. Jimeno A, et al. Among authors: stagg r. Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27. Clin Cancer Res. 2017. PMID: 28954784 Clinical Trial.
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Dotan E, Cardin DB, Lenz HJ, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. Dotan E, et al. Among authors: stagg rj. Clin Cancer Res. 2020 Oct 15;26(20):5348-5357. doi: 10.1158/1078-0432.CCR-20-0489. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694153 Free PMC article. Clinical Trial.
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Fu S, et al. Among authors: stagg r. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. doi: 10.1200/JCO.21.01801. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439029 Free PMC article. Clinical Trial.
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. Moore KN, et al. Among authors: stagg r. Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4. Gynecol Oncol. 2019. PMID: 31174889 Free PMC article. Clinical Trial.
77 results